## DisclosureEquityIncentivePlansTables

**Year Ended**

|  | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 |
| --- | --- | --- | --- |
| **  Summary of Stock Option and RSU Activity Under Plan** | The following table summarizes stock option and RSU activity under the 2010 
Plan:

                                                                                
         Weighted-                         Weighted-              
                                                              Weighted-         
Average                           Average                
                                                              Average           
Remaining                         Grant                  
                                                              Exercise          
Contractual                       Date Fair              
                                                              Price             
Life (Years)                      Value                  
  Balance, December 31, 2015                  20,015,180      $               
46.14                         2,439,674      $              219.90  
  Assumed through acquisition                  1,304,104                     
283.35                           382,611                     185.04  
  Granted                                        853,960                     
211.10                         2,797,973                     202.59  
  Exercised                                   (8,735,830                      
12.84                                 —                          —  
  Cancelled                                     (561,992                     
218.58                          (519,908                     215.07  
  Released                                             —                        
—                        (1,018,261                     212.96  
  Balance, December 31, 2016                  12,875,422      $               
96.50                         4,082,089      $              207.11  
  Vested and expected to vest,                12,875,422      $               
96.50                         4,082,089                             
  Exercisable and vested,                      7,817,124      $               
77.70                                 —                             
  *Aggregate intrinsic value in billions
 |  |  |
| **  Schedule of Fair Value of Option Award and ESPP on Grant Date** | We utilize the fair value method in recognizing stock-based compensation 
expense. Under the fair value method, we estimated the fair value of each option
award and the ESPP on the grant date generally using the Black-Scholes option 
pricing model and the weighted-average assumptions noted in the following table.

                                 Year Ended December 31,                        
                                                    2016                        
 ───────────────────────────────────────────────────────────────────────────────
──────
  Risk-free interest rate:                                                      
  Stock options                                               1.5      1.6      
1.9  
  ESPP                                                        0.6      0.3      
0.1  
  Expected term (in years):                                                     
  Stock options                                               6.2      5.4      
6.0  
  ESPP                                                        0.5      0.5      
0.5  
  Expected volatility:                                                          
  Stock options                                                47       48      
55  
  ESPP                                                         41       42      
46  
  Dividend yield:                                                               
  Stock options                                               0.0      0.0      
0.0  
  ESPP                                                        0.0      0.0      
0.0
 |  |  |
| **  Summary of Stock-Based Compensation Expense** | The following table summarizes the stock-based compensation expense by line item
in the consolidated statements of operations (in thousands):

                                           Year Ended December 31,              
                                           2016                                 
2015                   2014               
 ───────────────────────────────────────────────────────────────────────────────
────────────────────────────────────────────────
  Cost of sales                            $                             30,400 
$          19,244      $          17,454  
  Research and development                                              154,632 
89,309                 62,601  
  Selling, general and administrative                                   149,193 
89,446                 76,441  
  Total                                    $                            334,225 
$         197,999      $         156,496
 |  |  |